“…Recently, DWI has been introduced as a new imaging modality that provides both morphological and functional information regarding characterization of lymphomas, and it has been used in detecting and staging malignant lymphomas, as well as in monitoring the response to therapy (1,2). However, it could not distinguish between diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (3,4). Positron emission tomography with the use of 2-deoxy-2-[ 18 F]fluoro-dglucose tracer could differentiate aggressive from indolent lymphoma and guide biopsies in the detection of histological transformation of indolent lymphoma (5,6).…”